Myriad, Clovis to Jointly Support Regulatory Development of Advanced Ovarian Cancer Therapy Rubraca

Myriad, Clovis to Jointly Support Regulatory Development of Advanced Ovarian Cancer Therapy Rubraca
Myriad Genetics will support the post-marketing regulatory development of Clovis Oncology‘s drug Rubraca (rucaparib) to treat women with BRCA-positive advanced ovarian cancer who have already received two or more chemotherapies. The U.S. Food and Drug Administration (FDA) granted Rubraca accelerated approval in December 2016. But the Clovis genetic test approved with the drug does not distinguish between inherited and acquired BRCA mutations.

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *